Particularly, the combination of ctDNA and tumor markers that patients with GC were often recommended to detect in regular examination during follow‐up (CEA, CA19‐9, and CA72‐4) presented a remarkably higher efficacy with an AUC of 0.940 (p = 0.002). Here, CEACAM5 is linked to neoplasm.